Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Discovery Network Motor neuron disease (MND) research

My Name’5 Doddie Foundation

People living with MND urgently need effective treatments. To catalyse the search for these treatments, the Discovery Network was first launched in 2024, with details of this first round now available here.

The Discovery Network is a new funding opportunity for interdisciplinary, multi-institutional teams to apply for £1 million over 3 years. Teams will take on bold ideas and innovative approaches to better understand the biology of MND, with a focused goal of identifying new therapeutic targets. The Network will be underpinned by a culture of collaboration and open science. My Name’5 Doddie Foundation will facilitate activities of the network and create opportunities for rapid translation of promising findings.

Aligned to the UK MND Research Institute, the Discovery Network will be joined up within the UK MND research ecosystem, enabling access to expertise and creating a national translational pipeline.

Scope

Each team will focus on a specific area of MND biology and build on existing expertise, knowledge and tools already developed and accessible within the team. Examples of areas of MND biology may include: autophagy, ageing, the immune system, lysosomal function, mitochondrial function, protein homeostasis, RNA metabolism and vesicle transport, although this is not an exhaustive list. The Foundation welcomes proposals in new or emerging areas of MND research if supported by robust scientific evidence. Successful applications will provide preliminary data linking the focus of their project to MND development or progression and outlining the potential to reveal new therapeutic targets.

Due to the previously successful teams’ focus on TDP-43 and ribonucleoprotein biology, other areas may be prioritised by the Advisory Board to diversify the projects within the Discovery Network.

Teams will employ a range of innovative techniques, methodologies and expertise to gain new disease insights. This may include new approaches in omics technologies, functional genomics, imaging, complex cell models, artificial intelligence and data-driven research. We encourage the use of a range of models including human iPSCs, animal models (where absolutely needed) and human tissue samples. Use of high quality patient datasets are also encouraged.

Application process and timeline

All applications are to be made using our online grant management system, Flexi-Grant. Key dates are tentatively outlined below:

RFA Released - 24th March 2025
Expressions of Interest due - Midday 21st May 2025
Full application invitations - End of June 2025
Full applications due - Midday 9th September 2025
Reviewer comments shared with applicants - w/c 10th October 2025
Response letter due - 24th October 2025
Decisions communicated - December 2025
Research begins - March/April January 2026

Assessment criteria

Applications will be assessed by our independent Advisory Board according to the following criteria:

Scientific merit of the study including ambition of the aims and objectives, proposed methodology, resources and equipment and level of scientific innovation
Technical feasibility of the project plan and likelihood of study aims and objectives being reached
Potential impact of the project, based on its ability to reveal promising new targets for future MND treatments
Suitability of the team to carry out the research, including access to relevant expertise and capabilities
Ability of the team to bring valuable tools, capabilities or resources to the Discovery Network
Likelihood of a successful collaboration across the team
Commitment of the team to open science and collaboration
A cost-effective and realistic budget

Specialties

Neurosciences

Eligibility Requirements

Teams must be interdisciplinary and multi-institutional (minimum 2 separate research institutions)
The lead applicant must be based within a UK academic institution, but collaborators can be based elsewhere in the world
We encourage early career researchers (ECRs), such as senior postdoctoral researchers working towards independence, to apply as lead and/or co-applicants; they must provide a letter of support from their research institution and head of laboratory for their application. Depending on the experience of the ECR applicant, the Advisory Board may request that the head of laboratory/mentor and ECR be co-lead investigators on the project to ensure adequate support and mentorship for the ECR lead.
Commercial companies (such as pharmaceutical and biotech companies) can be named as co-applicants but will not receive grant funding and must adhere to our policies including our open science policy

Each team will receive up to £1 million. The total fund available in 2025 is £2 million.

Eligible Countries:

United Kingdom

Sponsor Details

Sponsor Institute/Organizations: My Name’5 Doddie Foundation

Sponsor Type: Corporate/Non-Profit

Address: Thorn House 5 Rose Street Edinburgh EH2 2PR

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity